LSPN Connect: Invention harvesting

In the fast-paced environment of life sciences, the need for the IP sector to take full advantage of potential and emerging innovations is paramount, as a LSPN Connect session discovered.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

LSPN 19: AI ‘explosion’ and drug costs in Canada

17 October 2019 Uncertainty surrounding the patentability of artificial intelligence (AI) and changes to patented medicine pricing in Canada were two topics discussed yesterday, October 15 at Life Sciences Patent Network Fall in San Francisco.

Americas

LSPN 19: Courts need to revisit patentability of diagnostic tests

26 April 2019 US courts need to revisit the patentability of diagnostic tests under section 101, according to Memorial Sloan Kettering Cancer Center’s chief IP counsel.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

LSPN Connect: Invention harvesting

More on this story

Editor's picks

Editor's picks

More features